How does chronic edema impact health-related quality of life?

How does chronic edema impact health-related quality of life?

How does chronic edema impact health-related quality of life?

IMAGE

IMAGE: Lymphatic Research and Biology delivers the latest developments and advances in lymphatic biology and pathology from the world’s leading biomedical investigators.
view more 

Credit: Mary Ann Liebert, Inc., publishers

New Rochelle, NY, April 26, 2019–Final results of the large, international LIMPRINT study have provided new data on the prevalence of chronic swelling and the devastating impact it can have on health-related quality of life. A broad range of articles that give a comprehensive view of the conceptual design, implementation, results, and interpretation of the LIMPRINT findings are published in a special issue of Lymphatic Research and Biology, a peer-reviewed online journal from Mary Ann Liebert, Inc., publishers. Click here to read the open access special issue on the Lymphatic Research and Biology website.

Chronic edema caused by the relative failure of the lymphatic system is mistakenly thought of as a rare condition, when, in fact, it is not only a relatively common, universal medical problem, but also very difficult to treat. Insufficient data have not been available to estimate the size of the affected population and, thus, to support the extensive impact of this disease. In response to this need, the International Lymphoedema Framework coordinated and completed the Lymphedema Impact and Prevalence project (LIMPRINT) on a worldwide scale.

In this special issue of Lymphatic Research and Biology, Christine Moffatt, PhD, MA, RGN, CBE, School of Social Sciences, Nottingham Trent University (Nottingham, U.K.) and colleagues from Royal Derby Hospital (Derby, U.K.) and Université de Montpellier (Montpellier, France) co-authored the article entitled “The Concept of Chronic Edema–A Neglected Public Health Issue and an International Response: The LIMPRINT Study.” The authors describe LIMPRINT, the difference between lymphedema and chronic edema and how the definitions of these conditions are changing, and they explore the complex patient profiles and new understanding of the underlying physiology. They also provide an overview and comparison of recent epidemiology studies.

Also featured is the article “LIMPRINT: Health-Related Quality of Life in Adult Patients with Chronic Edema,” by Gregoire Mercier, MD, PhD, MSc, CHU de Montpellier and CNRS Université de Montpellier (Montpellier, France) and a team of researchers from Nottingham Trent University (Nottingham, U.K.) and Centre for Research & Implementation of Clinical Practice (London, U.K.). Chronic edema had a considerable impact on patient self-reports of health-related quality of life, and the impact was greater with leg compared to arm chronic edema.

“The nearly universal neglect of lymphedema has been both paradoxical and frustrating to patients and health care providers alike. As the Editor-in- Chief, I am proud to have our journal serve as the publication medium for this important work. The availability of the LIMPRINT data is groundbreaking and should provide a much-needed paradigm shift,” says Stanley G. Rockson, MD, Editor-in-Chief of Lymphatic Research and Biology and Allan and Tina Neill Professor of Lymphatic Research and Medicine, Stanford University School of Medicine, CA.

###

About the Journal

Lymphatic Research and Biology is an authoritative peer-reviewed journal published bimonthly in print and online that delivers the latest developments and advances in lymphatic biology and pathology from the world’s leading biomedical investigators. Topics covered include vasculogenesis and angiogenesis, genetics of lymphatic disorders, human lymphatic disease, tumor biology and metastasis, pharmacology, lymphatic imaging, and inflammation, infection, and autoimmune disease. Complete tables of contents and a sample issue may be viewed on the Lymphatic Research and Biology website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cancer Biotherapy and Radiopharmaceuticals and DNA and Cell Biology. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read More